Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220135 · ClinicalTrials.gov registry record · Phase 2
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07220135 is a Phase 2 study that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 100 participants.
The verdict
NCT07220135, a Phase 2 study, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Trastuzumab (or biosimilar)
- DRUG Pertuzumab (or biosimilar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2031-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220135
The ClinicalTrials.gov registry entry for NCT07220135 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT07220135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07220135 about?
NCT07220135 is a clinical study titled "Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer". This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.
What is the current status of trial NCT07220135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-11-14. Estimated completion is 2031-05-14.
What interventions are being tested in trial NCT07220135?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Trastuzumab (or biosimilar) (DRUG), Pertuzumab (or biosimilar) (DRUG).
Who is sponsoring clinical trial NCT07220135?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.